Healwell AI Inc. (AIDX.TO TSX) +10% intraday 25 Feb 2026: key signals to watch
Healwell AI Inc. (AIDX.TO) gained 10.00% intraday to C$0.66 on 25 Feb 2026, driven by a volume spike to 198,686 shares. The move follows renewed attention to the company’s AI-enabled preventative-care platform and its strategic alliance with WELL Health Technologies. Our intraday AIDX.TO stock update connects technical signals, key ratios, and Meyka AI’s model forecast to explain short-term momentum and medium-term valuation risks.
Intraday price action and volume context for AIDX.TO stock
AIDX.TO stock opened at C$0.66, traded between C$0.625 and C$0.67 today, and closed up C$0.06 versus the previous close of C$0.60. Daily volume of 198,686 is below the 50-day average of 506,645, yet the 10.00% gain and relative volume of 0.61 suggest fresh buying interest. Year range remains wide at C$0.58–C$1.81, leaving room for volatility in the near term.
Fundamentals and valuation snapshot for AIDX.TO stock
Healwell AI shows a market cap of C$175.39M and 278,397,768 shares outstanding. Trailing EPS is -0.23 with a negative PE of -2.74, signaling loss-making operations. Key ratios: P/S 1.75, P/B 1.25, and current ratio 0.85. Cash per share is C$0.07 and debt-to-equity is 0.74, reflecting modest leverage for a small-cap healthcare tech issuer. These metrics frame why investors view AIDX.TO stock as speculative.
Technical read: momentum, trend and risk signals for AIDX.TO stock
On technicals AIDX.TO stock shows RSI 32.49 (near oversold) and ADX 40.41, which indicates a strong trend. MACD is slightly negative (-0.06). Bollinger bands (Lower C$0.54, Middle C$0.72, Upper C$0.89) suggest price is below the 20-day mean. Short-term indicators point to defensive stops for traders and potential short-term mean reversion if volume remains supportive.
Growth, cash flow and operational highlights shaping AIDX.TO stock
Revenue per share TTM is C$0.42, with net income per share TTM -0.25 and free cash flow per share -0.11. R&D spend runs near 20% of revenue, showing a product development focus. Receivables and working capital metrics signal longer cash conversion (DSO 135 days) that can strain liquidity for growth. These operational facts explain the negative earnings and the stock’s low price averages (50‑day C$0.82, 200‑day C$1.21).
Meyka AI grade and model forecast for AIDX.TO stock
Meyka AI rates AIDX.TO with a score out of 100: Score 53.84 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects Monthly C$0.41, Quarterly C$0.56, and Yearly C$0.43. Versus the current C$0.66, the 12‑month projection implies an approximate -34.85% downside. Forecasts are model-based projections and not guarantees.
Catalysts, sector context and near-term trading strategy for AIDX.TO stock
Catalysts include the company’s alliance with WELL Health Technologies and the upcoming earnings announcement on 26 Mar 2026. The Canadian healthcare sector has mixed recent performance; sector investors favor profitable biotechs and health techs with stable margins. For AIDX.TO stock, risk-managed strategies include scaling in on confirmed volume breakouts, using tight stops, or waiting for a sustained move above the 50-day average C$0.82 before adding exposure.
Final Thoughts
Short-term momentum pushed Healwell AI (AIDX.TO) to C$0.66 on 25 Feb 2026, but the company still shows loss-making fundamentals and tight liquidity metrics. Our Meyka AI forecast model projects a 12‑month price of C$0.43, implying roughly -34.85% from today’s price; the quarterly model sits at C$0.56. Technicals show a strong trend but a near-oversold RSI, which can produce intraday bounces that do not change the medium-term outlook. Investors focused on AIDX.TO stock should weigh speculative upside from AI-healthcare adoption against negative earnings, a current ratio under 1.0, and long DSO. For traders, look for confirmation above C$0.82 (50‑day MA) with expanding volume. For longer-term investors, reassess after the next earnings report and any concrete commercial milestones tied to the WELL Health alliance. Meyka AI provides this as AI-powered market analysis; these grades and forecasts are model-based and not investment advice.
FAQs
What drove today’s move in AIDX.TO stock?
The intraday 10.00% gain in AIDX.TO stock came on higher trading interest and renewed focus on Healwell AI’s partnership activity. Volume rose to 198,686 shares, indicating fresh buying, but fundamentals and liquidity still limit confidence for long-term investors.
What is Meyka AI’s price projection for AIDX.TO stock?
Meyka AI’s model projects Yearly C$0.43, Quarterly C$0.56, and Monthly C$0.41 for AIDX.TO stock. The 12‑month figure implies about -34.85% vs current price. Forecasts are projections and not guarantees.
Which metrics matter most when evaluating AIDX.TO stock?
Key metrics for AIDX.TO stock are EPS (-0.23), PE (-2.74), current ratio (0.85), cash per share (C$0.07), and DSO (135 days). These reflect profitability, liquidity and cash conversion risks.
How should traders manage risk around AIDX.TO stock?
Traders should use tight stops and watch volume and the 50‑day MA (C$0.82). Confirm a breakout with rising volume before increasing position size. Given volatility, limit allocation and set clear exit levels.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.